

### **Aalborg Universitet**

#### Quality of life in individuals with patellofemoral pain

A systematic review including meta-analysis

Coburn, Sally L; Barton, Christian J; Filbay, Stephanie R; Hart, Harvi F; Rathleff, Michael S; Crossley, Kay M

Published in: Physical Therapy in Sport

DOI (link to publication from Publisher): 10.1016/j.ptsp.2018.06.006

Creative Commons License CC BY-NC-ND 4.0

Publication date: 2018

Document Version Accepted author manuscript, peer reviewed version

Link to publication from Aalborg University

Citation for published version (APA): Coburn, S. L., Barton, C. J., Filbay, S. R., Hart, H. F., Rathleff, M. S., & Crossley, K. M. (2018). Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis. *Physical Therapy in Sport*, 33, 96-108. https://doi.org/10.1016/j.ptsp.2018.06.006

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
   You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: June 18, 2025

# **Accepted Manuscript**

Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis

Sally L. Coburn, Christian J. Barton, Stephanie R. Filbay, Harvi F. Hart, Michael S. Rathleff, Kay M. Crossley

PII: S1466-853X(18)30192-5

DOI: 10.1016/j.ptsp.2018.06.006

Reference: YPTSP 918

To appear in: Physical Therapy in Sport

Received Date: 10 May 2018

Accepted Date: 22 June 2018

Please cite this article as: Coburn, S.L., Barton, C.J., Filbay, S.R., Hart, H.F., Rathleff, M.S., Crossley, K.M., Quality of life in individuals with patellofemoral pain: A systematic review including meta-analysis, *Physical Therapy in Sports* (2018), doi: 10.1016/j.ptsp.2018.06.006.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



TITLE PAGE

Quality of Life in Individuals with Patellofemoral Pain: A Systematic Review Including

Meta-analysis.

Sally L. Coburn, PT, MSc<sup>1</sup>, Christian J. Barton, PT, PhD<sup>1</sup>, Stephanie R. Filbay, PT, PhD<sup>2</sup>,

Harvi F. Hart, PhD<sup>1</sup>, Michael S. Rathleff, MD, PhD<sup>3,4</sup>, Kay M. Crossley, PT PhD<sup>1</sup>.

<sup>1</sup>La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, La Trobe

University, Bundoora, Victoria, Australia.

<sup>2</sup>Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Nuffield Department of

Orthopaedics, Rheumatology & Musculoskeletal Science, Botnar Research Centre,

University of Oxford, Oxford, England.

<sup>3</sup>Research Unit for General Practice in Aalborg, Department of Clinical Medicine, Aalborg

University, Denmark.

<sup>4</sup>Department of Occupational therapy and Physiotherapy, Aalborg University Hospital,

Denmark.

PROSPERO registration number: CRD42016026307

WORD COUNT: abstract: 200 words; manuscript: 4012 words (excluding key words,

highlights, figures, tables and references)

ADDRESS FOR CORRESPONDENCE

Kay M Crossley

La Trobe Sport and Exercise Medicine Research Centre

School of Allied Health, College of Science, Health and Engineering

La Trobe University, Bundoora Vic. 3086 Australia

Tel: +61 3 9479 3902

Fax: +61 3 9479 5768

E-mail: k.crossley@latrobe.edu.au

## 1 ANONYMOUS TITLE PAGE

2

- 3 Quality of Life in Individuals with Patellofemoral Pain: A Systematic Review Including
- 4 Meta-analysis.

5

6

8	ABSTRACT	Γ
•		•

- 9 **Objective:** The aim of this systematic review is to describe QoL in individuals with PFP, and
- determine the impact of PFP interventions on QoL.
- 11 Methods: Five databases were searched for studies reporting QoL in individuals with PFP,
- with mean age under 50 years. Data were pooled based on QoL tool (e.g. Knee Injury and
- Osteoarthritis Outcome Score [KOOS] QoL subscale, Short-Form 36 item health survey [SF-
- 14 36]) using random-effects models, or through narrative synthesis where inadequate data were
- available.
- Results: Individuals with PFP, had worse KOOS-QOL scores (pooled mean: 47[95% CI: 34
- to 61] and health-related QoL (pooled SF-36 PCS and MCS: 47[95% CI: 41 to 53] and
- 18 54[95% CI: 47 to 62], respectively) compared with pain-free controls and population norms.
- 19 Physical interventions were associated with improvements in knee- and health- related QoL
- 20 in individuals with PFP in repeated measures studies. However, the effect of physical
- 21 interventions compared to a control treatment was conflicting.
- 22 Conclusion: Individuals with PFP aged under 50 years, have markedly reduced knee- and
- 23 health-related QoL compared to pain-free controls and population norms. Knee- and health-
- 24 related QoL may improve following intervention, but it is unclear if these improvements are
- 25 greater than that which occur in a control group.
- 26 **Keywords:** anterior knee pain, patellofemoral pain syndrome, KOOS, SF-36, intervention

27

28

## 1. INTRODUCTION

- 29 Patellofemoral pain (PFP) is a common disorder of the knee,<sup>55</sup> prevalent in adolescent<sup>31</sup> and
- 30 adult populations, 62 and particularly prevalent in physically active individuals. 35 PFP is a
- 31 chronic, painful condition predominantly of insidious onset, which often persists despite
- 32 provision of evidence-based treatments.<sup>37</sup> Research suggests that 57% of individuals with

PFP may experience persistent symptoms and unfavourable outcomes 5-8 years after
enrolment in a clinical trial. <sup>28</sup> Moreover, symptom severity may remain unchanged or
progress in 50% of affected individuals, <sup>7</sup> often restricting an individual's participation in
physical activity <sup>40</sup> and potentially reducing quality of life (QoL).

Health-related QoL is a multi-dimensional concept, encompassing physical, psychological and social aspects associated with a disease or its treatment.<sup>19</sup> Disease-specific and generic health-related QoL measures are used to evaluate patient experience of a musculoskeletal condition and the benefit of therapeutic interventions.<sup>46</sup> The patients' perspective and experience should be paramount when evaluating the impact of a condition or the efficacy of an intervention.<sup>45</sup> The use of QoL instruments recognizes that patient perceptions do not always match with knee pathology<sup>50</sup> or findings from a clinical examination of the knee.<sup>24</sup> Although rarely the primary outcome of interest, knee- and health- related QoL outcomes have been reported in a number of studies investigating individuals with PFP, and have been used to evaluate intervention efficacy for this condition. Synthesis of this evidence will provide a better understanding of the impact of PFP and the influence of specific treatment strategies on OoL.

This systematic review aims to: (i) describe QoL in individuals with PFP compared to painfree controls and population norms; (2) evaluate whether intervention is associated with improved QoL in individuals with PFP; and (3) identify factors associated with QoL in individuals with PFP.

#### 2. METHODS

- 57 This systematic review followed the Preferred Reporting Items for Systematic reviews and
- 58 Meta-Analysis (PRISMA) guidelines,<sup>30</sup> with the protocol prospectively registered on
- 59 PROSPERO (http://www.crd.york.ac.uk/PROSPERO/; CRD 42016026307, 12 April 2016).
- There were no peer-reviewed literature reviews of this topic at the time.

61

62

### 2.1 Literature Search Strategy

- A comprehensive search strategy was devised for the following electronic databases: (i)
- 64 AMED, (ii) CINAHL via EBSCO, (iii) Cochrane Central Register of Controlled Trials, (iv)
- 65 EMBASE via OVID, and (v) MEDLINE via OVID. Diagnostic search terms from a
- 66 Cochrane systematic review of exercise interventions for individuals with PFP were used to
- 67 identify PFP literature;<sup>54</sup> and combined with terms for QoL measurement tools, similar to the
- strategy used by Filbay et al, 2014.<sup>17</sup> The search strategy for MEDLINE is presented in
- 69 Appendix 1, and was adjusted to suit other databases. All potentially eligible papers were
- 70 imported into EndNote X7.2.1 (Thomson Reuters, Carlsbad, California, USA) and duplicates
- 71 were removed. The search was conducted in April, 2016. Two reviewers (X and Y)
- 72 independently screened the titles and abstracts of all articles using a checklist based on the
- eligibility criteria. Papers with insufficient information in title and abstract to determine
- eligibility were retained for full-text evaluation using the same checklist. Reference lists of all
- 75 publications considered for inclusion were hand-searched and citation tracking was
- 76 completed using Google Scholar. The final lists of eligible articles were compared between
- the two reviewers, with a third reviewer available to resolve any disagreement (Z).

78

79

#### 2.2 Selection Criteria

- All studies reporting QoL in individuals with PFP were included, regardless of study design
- 81 methodology. Participants in the studies were required to be experiencing PFP/retropatellar

knee pain/anterior knee pain or be diagnosed with chondromalacia patella. Studies were excluded if participants had other knee conditions (such as a ligament or meniscal injury, patellar tendinopathy, recurrent patella subluxation, diagnosed radiographic osteoarthritis or were preoperative patients awaiting surgery for their PFP). No other treatment intervention was excluded. To reduce the likelihood that a proportion of study participants may have undiagnosed patellofemoral osteoarthritis (PFOA) studies of participants with mean age of greater than 50 years were excluded from this systematic review. Studies not published in English, French, German or Danish were ineligible. In the case of multiple studies using the same cohort, the study reporting QoL outcomes for the largest sample size was included.

## 2.3 Assessment of Reported Methodological Quality

Two independent reviewers (X, W) rated the reported methodological quality of included studies using two separate scales. The first scale was a checklist adapted from the 21-item Downs and Black checklist which is suitable for randomised and non-randomised studies (Appendix 2)<sup>15</sup>. Items were scored according to the method used by Downs and Black (1998): 'Yes' (score=1), 'No' (score=0), or 'Not Applicable' (items removed from scoring), except for Item 5 (i.e. description of principle confounders clearly described) which was scored 'Yes' (score=2), 'Partially' (score=1) or 'No' (score=0). Items considered not applicable to assess intervention studies were removed, resulting in a modified checklist of 15 items. One of the 15 items, concerning follow-up, was not applicable to cross-sectional studies and 6 items were not applicable to validity and reliability studies so were removed from scoring, leaving 14 and 8 items, respectively. Therefore a percentage score was calculated from relevant items for the three different study designs. The median value was identified to assign a level of methodological quality. Studies were classified as higher reported quality (study)

score equal to or greater than the median value) and lower reported quality (study score less than the median value).  $^{38}$ 

The second scale used was The Cochrane Risk of Bias Tool.<sup>22</sup> This tool is specifically used for controlled intervention studies to provide explicit assessment of each component risk of bias.<sup>58</sup> The additional quality assessment tool provided more comprehensive evaluation of intervention study outcomes to inform the second aim of this review. The Cochrane Risk of Bias Tool is comprised of a 7 domain checklist to assess selection bias (2 domains), performance bias (1 domain), detection bias (1 domain), attrition bias (1 domain), reporting bias (1 domain), and other bias (1 domain). Domains were recorded as low or high risk of bias or risk of bias unclear. Risk of bias within studies was summarised as low risk (low risk of bias for all domains), unclear risk (low or unclear risk of bias for all domains), or high risk (high risk of bias for one or more domain).<sup>22</sup> Any inter-rater disagreement was discussed in a consensus meeting and unresolved items were taken to a third reviewer (Z) for consensus. A level of evidence was assigned for intervention study data using the statistical outcomes and methodological quality of included studies, based on recommendations by van Tulder.<sup>56</sup>

## 2.4 Data Management and Statistical Analyses

Participant (e.g. sex, age, BMI) and study (e.g. study design) characteristics, QoL, and type of treatment for intervention studies, were independently extracted (X). If sufficient data were not reported in the published article or supplementary material provided, the corresponding author was contacted to request further information. Data were cross-checked by a second reviewer (V). When intervention studies reported QoL data at multiple time points post-treatment for PFP, data from the first follow-up after treatment were extracted. If BMI data were not reported, then it was estimated from mean height and mass data.

1	3	1

132

133

134

Normative QoL data were obtained from previously published population studies. Studies with QoL data available from the largest number of participants of a comparable age were selected. 9,23,29,33 Pain-free control data were obtained from included studies. 5,36,39,42

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Data were analyzed based on QoL instrument. Knee-related QoL was measured with the Knee injury and Osteoarthritis Outcome Score QoL subscale (KOOS-QoL). Health-related QoL was measured with: i) the 36-Item Short Form Survey (SF-36) reported as 8 domain scores and/or physical and mental component summary scores (PCS and MCS respectively), (ii) the 8-Item Short Form Survey (SF-8) reported as 8 domain scores, or (iii) the European QoL-5 Dimension (EQ-5D) index score. To address the first aim of this review, pooled mean [95% CI] QoL data from individuals with PFP, pain-free controls, and normative populations are presented. Baseline mean QoL scores from intervention studies were pooled with QoL data from all other studies. To address the second aim of this review, random effects metaanalyses were used to compare QoL between pre- and post-treatment for repeated measure design intervention studies and to compare QoL outcomes between treatment and control groups for controlled intervention studies (Review Manager Version 5.3). Pooled findings of intervention studies were considered heterogeneous if I<sup>2</sup> >50% was statistically significant (p<0.05). Standardized mean differences (SMD) [95% CI] are reported. The magnitude of the pooled SMD was interpreted based on Cohen's criteria, where SMD ≥0.8 was interpreted as a large effect, >0.5 and <0.8 a moderate effect, and >0.2 and <0.5 a small effect. 18

152

153

154

155

## 2.5 Deviations from study protocol

Initially, we were interested in exploring the association between secondary outcomes (i.e.

body mass index [BMI], age, pain) and QoL through a meta-regression analysis (ie. Aim 3).

However, due to a low number of included case-control studies for each QoL instrument, a
meta-analysis comparing QoL and secondary outcomes was not possible. Considering at least
10 studies should be included in a meta-analysis for each covariate in order for a meta-
regression analysis to be meaningful, it was not possible to conduct the planned meta-
regression analysis8. Additionally, the Cochrane risk of bias tool22 was added to enhance
examination of the risk of bias of included randomized controlled trials (RCT).

## 3.0 RESULTS

## 3.1 Search Strategy, Methodological Quality, and Risk of Bias

The comprehensive search strategy identified 1573 titles, with 1304 titles and abstracts evaluated after removal of duplicates. The full-text of 93 articles were retrieved and assessed for eligibility. Two additional papers were identified by citation tracking, and four were identified in an updated search performed prior to final data analysis using the same search strategy, in January, 2017. Twenty-one studies met the selection criteria (Figure 1).




FIGURE 1: Flow chart of the study selection process.

Thirteen authors (for 15 studies) were contacted to obtain raw data, 10 responded and of these, 8 supplied data for 9 studies<sup>4,11,14,32,34,36,41,47,57</sup>. QoL data were extracted for 1111 individuals with PFP and 100 pain-free controls. Characteristics of included studies are

presented in Table 1.

Study	PFP participants	Control participants	Aim/Comparison/ Intervention	Rx Duration	QOL measure(s)	Domain	PFP	Comparator
Cross-sectional								
Assa 2015	n = 157	n = 31, Pain-free	PFP compared to		SF-36	PF	65 [62 to 68]	97 [96 to 99]
(Israel)	Age = $30 (5)$	Age = $32(4)$	control			RP	40 [34 to 45]	97 [93 to101]
	BMI = 24 (3)	BMI = 23(3)				BP	50 [47 to 54]	92 [88 to 96]
	W = 42%	W = 45%				GH	65 [62 to 68]	82 [88 to 96]
						V	54 [51 to 57]	72 [67 to 75]
						SF	77 [73 to 80]	97 [95 to 100]
						RE	65 [58 to 71]	98 [95 to 101]
						MH	69 [67 to 72]	79 [76 to 83]
						PCS	55 [52 to 57]	88 [86 to 90]
			Y			MCS	66 [63 to 69]	86 [83 to 88]
Rathleff CR 2013	n = 20	n = 20, Healthy	PFP compared to		KOOS-QOL		54 [49 to 60]	98 [95 to 101]
(Denmark)	Age = $15(1)$	Age = $15(1)$	control		EQ-5D		0.72 [0.68 to 0.78]	1.0 [1.0 to 1.0]
	BMI = 20 (3)	BMI = 19(1)			(index)			
	W = 80%	W = 80%						
Rathleff MS 2013	n = 57∧	n = 29, Pain-free	PFP compared to		KOOS-QOL		54† [50 to 58]	99 [98 to 100]
(Denmark)	Age = $17(1)$	Age = $17(1)$	control					
	BMI = 21 (2)	BMI = 21 (3)						
	W = 100%	W = 100%						
Rathleff MS 2016	n = 20^	n = 20, Pain-free	PFP compared to		KOOS-QOL		55† [47 to 63]	97 [94 to 100]
(Denmark)	Age = $20 (20-21)$	Age = $21 (19-21)$	control					
	BMI =22* (NR)	BMI =22* (NR)						
	W = 100%	W = 100%						
Study	PFP	Control	Aim/Comparison/	Rx	QOL	Domain	PFP	Comparator
			Intervention	Duration	measures			
<b>Ch</b> eung 2013	Amateur athletes		Amateur compared to		SF-36	PF	88 [80 to 96]	

(China)	n = 19	professional athletes	RP	78 [59 to 96]	
	Age = $23(1)$	with PFP	BP	63 [54 to 72]	
	BMI = 20* (NR)		GH	66 [56 to 74]	
	W = NR		V	63 [55 to 72]	
			SF	83 [72 to 93]	
			RE	67 [45 to 88]	
			МН	74 [66 to 81]	
			PF	75 [67 to 82]	
	Professional		RP	42 [23 to 61]	
	athletes		BP	51 [54 to 72]	
	n = 19		GH	65 [56 to 74]	
	Age = $21 (2)$		V	55 [44 to 65]	
	BMI = 20* (NR)		SF	78 [71 to 86]	
	W = NR		RE	58 [37 to 79]	
			MH	65 [58 to 71]	
Silva 2016	Non-athletes	Non-athletes compared	KOOS-QOL	68 [62 to 74]	·
(Brazil)	n = 34	to athletes with			
	Age = $15(1)$	with PFP			
	BMI = 22* (NR)				
	W = 32%				
	Athletes			78 [70 to 86]	
	n = 22				
	Age = $14(1)$				
	BMI = 22 ()				
	W = 36%				
Vincent 2010	n=33	Knee pain (PFP	SF-8 PF	49 [46 to 52]	
(Australia)	Age = NR	subgroup obtained	RP	39 [36 to 42]	
	BMI = NR	from author)	BP	35 [30 to 39]	
	W = NR		GH	43 [41 to 46]	
			V	51 [48 to 53]	
			SF	46 [43 to 49]	

						RE	51 [49 to 54]	
Study	PFP	Control	Aim/Comparison/	Rx	QOL	Domain	PFP	Comparator
			Intervention	Duration	measures			
Vincent 2010	n=33		Knee pain (PFP		SF-8	MH	48 [46 to 51]	
(Australia)	Age = NR		subgroup obtained			PCS	40 [36 to 44]	
(Continued)	BMI = NR		from author)			MCS	54 [51 to 57]	
	W = NR							
Validity and reliabili	ty							
Apivatgaroon 2016	n = 49		Testing validity &		SF-36	PF	33 [26 to 39]	
(Thailand)	Age = $47(11)$		reliability of Kujala in			RP	54 [48 to 60]	
	BMI = 25 (5)		PFP			BP	42 [37 to 47]	
	W = 80%					GH	47 [41 to 54]	
						V	52 [47 to 57]	
						SF	54 [49 to 59]	
						RE	55 [49 to 62]	
						MH	59 [53 to 64]	
						PCS	46 [41 to 50]	
			Y			MCS	53 [49 to 58]	
Cheung 2012	n = 64		Testing validity &		SF-36	PF	88 [85 to 91]	
(China)	Age = $30 (6)$		reliability			RP	76 [68 to 84]	
	BMI = 22*(NR)		Kujala in PFP			BP	58 [52 to 63]	
	W = 41%					GH	64 [60 to 69]	
						V	62 [58 to 66]	
						SF	84 [79 to 89]	
						RE	79 [70 to 88]	
						MH	73 [69 to 76]	
Negahban 2013	n = 100		Validity & reliability of		SF-36	PF	65 [60 to 70]	
(Iran)	Age = $25(7)$		Functional Index			RP	48 [40 to 55]	
	BMI = 23*(NR)		Questionnaire &			BP	51 [47 to 55]	
	W = 71%	Y	Modified Functional			GH	54 [50 to 57]	
			Index Questionnaire in			V	58 [56 to 61]	
			individuals with PFP			SF	66 [62 to 70]	
						RE	45 [36 to 54]	

						MH	64 [61 to 67]	
						PCS	55 [52 to 58]	
						MCS	58 [54 to 61]	
Study	PFP	Control	Comparison or	Rx	QOL	Domain	PFP	Comparator
			Intervention	Duration	measures			
Controlled interver	ntion studies							
Crossley 2002	Treatment		Randomized controlled	6 weeks	SF-36	PF	64 [57 to 71]	79 [73 to 85]
(Australia)	n = 36		trial comparing change			RP	59 [47 to 72]	80 [70 to 91]
	Age = $29 (8)$		in QOL after active			BP	52 [45 to 59]	77 [71 to 83]
	BMI = 24 (4)		MMP in PFP vs.			GH	71 [64 to 76]	78 [72 to 84]
	W = 64%		change after placebo			V	55 [49 to 61]	64 [58 to 70]
			intervention in PFP	*		SF	67 [60 to74]	75 [69 to 81]
						RE	81 [69 to 93]	85 [75 to 95]
						MH	72 [67 to 77]	82 [78 to 86]
		Placebo		6 weeks		PF	64 [58 to 70]	82 [78 to 86]
		N = 34				RP	57 [40 to 68]	79 [68 to 90]
		Age = $26 (8)$				BP	52 [44 to 58]	72 [65 to 79]
		BMI = 25 (4)				GH	71 [64 to 78]	77 [72 to 83]
		W = 66%				V	56 [51 to 63]	63 [57 to 69]
						SF	69 [63 to 76]	80 [73 to 87]
			, , , , , , , , , , , , , , , , , , ,			RE	73 [60 to 86]	89 [82 to 96]
						MH	75 [70 to 81]	81 [77 to 85]
Petersen 2016	MMP & brace		Randomized trial	6 weeks	KOOS-QOL		40 [37 to 44]	69 [65 to 72]
(Germany)	n = 78		comparing change in					
	Age = $28 (9)$		QOL following					
	BMI = 23 (2)		MMP					
	W = 51%		& brace intervention					
			vs. MMP alone					
	MMP	Y		6 weeks			43 [40 to 45]	60 [55 to 65]
	n=78							
	Age = $28 (8)$							

BMI = 23 (1)W = 61%

Study	PFP	Control	Comparison or	Rx	QOL	Domain	PFP	Comparator
			Intervention	Duration	measures			
Rathleff MS 2014	Physiotherapy +		Cluster randomized	12 weeks	KOOS-QOL		57 [52 to 61]	62 [54 to 71]
(Denmark)	Education		trial comparing change					
	n = 62		in QOL following					
	Age = $17(1)$		supervised					
	BMI = 21 (3)		physiotherapy +					
	W = 74%		education vs. education					
			alone					
	Education			4				
	n = 59			12 weeks			53 [49 to 57]	54 [52 to 57]
	Age = $17(1)$							
	BMI = 22 (3)							
	W = 86%							
Syme 2011	VMO training		Randomized controlled	8 weeks	SF-36	PCS	45 [42 to 48]	53 [49 to 58]
(UK)	n = 23		trial comparing change			MCS	45 [42 to 48]	46 [42 to 51]
	Age = $29 (8)$		in QOL following					
	BMI = 26 (1)		vastus medialis oblique					
	W = 57%		selective training vs.					
			general quadriceps					
			strengthening					
	Quadriceps			8 weeks		PCS	47 [43 to 50]	54 [49 to 60]
	strengthening					MCS	47 [43 to 50]	50 [47 to 54]
	n = 23							
	Age = $27 (8)$							
	BMI = 26 (1)							
	W = 57%	X .						
		No treatment		8 weeks		PCS	47 [43 to 50]	40 [32 to 48]
		n = 23				MCS	47 [43 to 50]	49 [44 to 54]

Age = 29 (6) BMI = 26 (1) W = 65%

Study	PFP	Control	Comparison or Intervention	Rx Duration	QOL measures	Domain	PFP	Comparator
Repeated measure	e intervention studies							
Akkurt 2010	n = 22		Repeated measures	6 weeks	SF-36	PCS	40 [31 to 49]	63 [55 to 72]
(Turkey)	Age = $35 (8)$		study of QOL			MCS	51 [41 to 60]	67 [59 to 75]
	BMI = NR		following isokinetic					
	W = 100%		exercise					
Banan 2016	n = 25		Repeated measures	4 weeks	KOOS-QOL		12 [8 to 15]	13 [9 to 17]
(Iran)	Age = $35 (10)$		study of QOL	4				
	BMI = 25 (7)		following rigid taping					
	W = 80%							
Eapen 2011	n = 20		Repeated measures	2 weeks	SF-36	BP	45 [40 to 51]	75 [69 to 80]
(India)	Age = $28 (7)$		study of QOL	<i>Y</i>		PCS	37 [35 to 39]	48 [46 to 49]
	BMI = NR		following eccentric			MCS	42 [39 to 45]	44 [43 to 46]
	W = 60%		exercise					
Haim 2013	n = 48		Repeated measures	26 weeks	SF-36	PF	61 [55 to 66]	64 [58 to 70]
(Israel)	Age = $31 (7)$		study of QOL			RP	42 [30 to 53]	54 [43 to 65]
	BMI = 24		following use of			BP	51 [44 to 57]	58 [53 to 64]
	W = 44%		biomechanical device			GH	60 [55 to 66]	65 [59 to 70]
			in shoe			V	50 [44 to 56]	54 [48 to 59]
						SF	76 [69 to 83]	81 [74 to 88]
						RE	69 [57 to 82]	73 [61 to 85]
						MH	68 [64 to 73]	68 [63 to 73]
						PCS	53 [47 to 58]	59 [54 to 64]
						MCS	65 [59 to 71]	68 [63 to 73]
Kuru 2012	Kinesio tape &		Repeated measures	6 weeks	SF-36	PF	41 [37 to 45]	49 [45 to 52]
(Turkey)	exercise	<b>X</b> '	study of QOL			RP	34 [29 to 39]	45 [41 to 50]
	n = 15		following Kinesio tape			BP	40 [36 to 44]	50 [47 to 53]
	Age = $33 (12)$		& exercise vs.			GH	40 [36 to 45]	44 [40 to 48]
	BMI = 24 (5)		Electrical stimulation			V	46 [42 to 49]	51 [47 to 54]

	W = 80%		+exercise			SF	42 [38 to 47]	47 [44 to 50]
						RE	39 [32 to 47]	50 [46 to 55]
						MH	40 [35 to 45]	44 [41 to 47]
Study	PFP	Control	Comparison or	Rx	QOL	Domain	PFP	Comparator
			Intervention	Duration	measures			
Kuru 2012	Electrical			6 weeks	SF-36	PF	39 [33 to 45]	48 [43 to 53]
(Turkey)	stimulation &					RP	43 [35 to 50]	53 [49 to 57]
(Continued)	exercise					BP	43 [38 to 49]	52 [49 to 54]
	n = 15					GH	43 [37 to 49]	46 [41 to 51]
	Age = $41 (11)$					V	44 [38 to 49]	48 [42 to 53]
	BMI = 27 (4)					SF	44 [39 to 49]	49 [44 to 54]
	W = 93%			* * *		RE	43 [34 to 51]	53 [48 to 57]
						MH	40 [33 to 46]	46 [41 to 50]
Sinclair 2016	n = 20		Repeated measures	2 weeks	KOOS-QOL		53 [47 to 58]	68 [60 to 76]
(UK)	Age = NR		study of QOL					
	BMI = NR		following brace use					
	W=45%							
Tsai 2015	n = 12		Repeated measures	6 weeks	KOOS-QOL		49 [36 to 62]	61 [48 to 74]
(USA)	Age = 39 (NR)		study of QOL					
	BMI = 23 (NR)		following off-axis					
	W = 75%		elliptical training					

Note. Demographic data are presented as mean (standard deviation), unless otherwise stated. Quality of life data are presented as mean [95% confidence interval]. Abbreviations as follows: PFP, patellofemoral pain; Rx, treatment; QOL, quality of life; BMI, body mass index (kg/m²); W, women; NR, not reported; KOOS, Knee Injury and Osteoarthritis Outcome Score; SF-36, Short-Form 36-Item Health Survey; PF, physical function; RP, role physical; BP, bodily pain; GH, general health; V, vitality; SF-social function; RE, role emotional; MH, mental health; SF-8, Short-Form 8-Item Health Survey; MMP, multi-modal physiotherapy; \* symbol denotes BMI not reported but estimated from height and mass; † is PFP participant data derived from participants included in largest cohort reported in 2014 paper

Eleven studies investigated the effect of a treatment intervention on QoL in PFP individuals.
Interventions included single treatment and multi-modal physical therapy, shoe inserts, braces
and elliptical training. The methodological quality scores ranged from 31-100%, with a
median score of 67% (Table 2). There were 12 studies of higher quality and nine studies of
lower quality. Of the four controlled intervention studies, there was one low risk of bias
study, one unclear, and two high risk of bias studies (Table 3).

**TABLE 2.** Reported methodological quality of the included studies.

Author	1	2	3	5	6	7	10	11	12	15	18	20	25	26	27	Score	Total	%	Quality
						QOL in	ı PFP (	cross-se	ction st	udies co	mpared	to cont	rol)						
Assa 2013	1	1	1	1	1	1	1	0	0	1	1	1	0	N/A	1	11	15	73	Higher
Rathleff CR 2013	1	1	1	2	1	1	1	1	0	1	1	1	1	N/A	0	13	15	87	Higher
Rathleff MS 2013	1	1	1	2	1	0	1	1	0	0	1	0	1	N/A	0	10	15	67	Higher
Rathleff MS 2016	1	1	1	2	1	1	1	1	0	1	1	1	1	N/A	1	14	15	93	Higher
	QOL in PFP (cross-section & validity studies)																		
Apivatgaroon 2016	1	1	1	N/A	1	1	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	6	8	75	Higher
Cheung 2012	1	1	1	N/A	1	0	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	5	8	63	Lower
Cheung 2013	1	1	1	2	1	1	1	0	0	0	0	1	1	N/A	1	11	15	73	Higher
Negahban 2013	1	1	1	N/A	1	1	N/A	0	0	N/A	N/A	1	N/A	N/A	N/A	6	8	75	Higher
Silva 2016	1	1	1	2	1	1	1	1	0	0	1	1	1	N/A	1	13	15	87	Higher
Vincent 2010	1	1	0	2	1	0	1	0	0	0	1	1	1	N/A	1	10	15	67	Higher
		•	•	Eff	fect of in	itervent	ion on Ç	QOL for	PFP (r	andomi	sed coni	trolled s	tudies)			•	<u>'</u>		•
Crossley 2002	1	1	1	2	1	1	1	1	0	1	1	1	1	1	1	15	16	94	Higher
Petersen 2016	1	1	1	1	1	0	0	1	0	0	1	1	1	0	1	10	16	63	Lower
Rathleff 2014	1	1	1	2	1	1	0	1	1	1	1	1	1	1	1	15	16	94	Higher
Syme 2009	1	1	1	2	1	1	0	1	1	1	1	1	1	1	1	15	16	94	Higher
		•	•	1	Effect of	interve	ntion or	i QOL fe	or PFP	(repeate	ed meas	ures stu	dies)			•	<u>'</u>		•
Akkurt 2010	1	1	1	0	1	1	1	0	0	0	0	0	0	0	0	6	16	38	Lower
Banan 2016	1	1	1	1	1	1	1	0	0	0	0	1	0	0	0	8	16	50	Lower
Eapen 2011	1	1	1	0	1	1	1	0	0	0	1	0	0	0	1	8	16	50	Lower
Haim 2013	1	1	1	1	1	1	1	0	0	0	1	0	0	N/A	1	9	15	60	Lower
Kuru 2012	1	1	1	1	1	1	1	0	0	0	0	0	0	1	0	8	16	50	Lower
Sinclair 2016	1	1	0	0	1	1	0	0	0	0	1	0	0	0	0	5	16	31	Lower
Tsai 2015	1	1	0	0	1	1	0	0	0	0	1	0	0	1	1	7	16	44	Lower

Note. N/A is not applicable. Higher quality is median score (67%) or above and lower quality is below median (<67%)

## **TABLE 3:** Risk of bias of included controlled intervention studies.

Study	Random sequence	Allocation concealment	Blinding of participants &	Blinding of outcome	Incomplete outcome data	Selective reporting	Other bias	Risk of bias within trial
	generation		personnel	assessment				
Crossley 2002	Low	Low	Low	Low	Low	Low	Low	Low risk
Petersen 2016	High	High	High	High	Unclear	Unclear	High	High risk
Rathleff 2014	Low	Low	Unclear	Low	Low	Low	Low	Unclear risk
Syme 2009	Low	Low	High	Low	Low	Low	High	High risk

*Low* risk of bias (bias if present is unlikely to alter the results seriously);

*Unclear* risk of bias (a risk of bias that raises some doubt about the results);

*High* risk of bias (bias may alter the results seriously)

## 3.3 QoL in Individuals with PFP

## Knee-related QoL in individuals with PFP

Seven studies reported knee-related QoL (KOOS-QoL) in individuals with PFP. 6,34,36,41,47,48,51

The pooled mean KOOS-QoL score from 7 studies (3 higher quality and 4 lower quality) in

214 individuals with PFP was 47 [95% CI: 34 to 61] (Figure 2).




FIGURE 2: Knee-related quality of life in individuals with patellofemoral pain.

One study considered an outlier (i.e. mean KOOS-QoL score (11) was outside the 95% CI for the pooled mean),<sup>6</sup> when excluded from the analysis, resulted in a pooled mean KOOS-QoL score of 53 [95% CI: 45 to 61]. A single study reported knee-related QoL in athletes with PFP (KOOS-QoL score, 78 [95% CI: 70 to 86]) (Table 4).<sup>47</sup>

**TABLE 4.** Quality of life in athletes with PFP compared to active population norms.

		Included studies	3	Active Population Norm	Mean difference			
	PFP-Pooled		2016 thletes	Cameron 2013	PFP Athletes v Active Norn			
KOOS- QoL	47 [34 to 61]	78 [70 to 86]		92 (12)	14			
SF-36	PFP-Pooled	Cheung 2013		Huffman 2008	Mean difference			
		PFP- Amateur athletes	PFP- Professional athletes		PFP Amateur athletes v Active Norm	PFP Professional athletes v Active Norm		
PF	59 [45 to 74]	88 [80 to 96]	75 [67 to 82]	99 [98 to 100]	11	24		
RP	50 (41 to 60]	78 [59 to 96]	42 [23 to 62]	96 [94 to 98]	18	54		
BP	49 [45 to 53]	63 [54 to72]	51 [41 to 62]	89 [87 to 91]	26	38		
GH	57 [50 to 66]	66 [56 to 76]	65 [56 to 74]	86 [85 to 88]	20	21		
V	54 [49 to 58]	63 [55 to72]	55 [44 to 65]	71 [69 to 73]	8	16		
SF	67 [55 to 79]	83 [72 to 93]	78 [71 to 86]	96 [95 to 98]	13	18		
RE	61 [50 to 73]	67 [45 to 88]	58 [37 to 79]	98 [97 to 99]	31	40		
МН	64 [55 to 72]	74 [66 to 80]	65 [58 to 71]	83 [82 to 85]	9	18		

All data reported as mean, [95%CI].


Active population norm reported in groups with no history of injury


## Knee-related QoL in individuals with PFP compared to population norms

The previously reported mean KOOS-QoL score from a general population sample of young adults was 84 [95% CI: 81 to 88]<sup>33</sup>. Based on the pooled scores, individuals with PFP had worse knee-related QoL relative to this general population sample (mean difference: 37; [KOOS-QOL 95% CI: 34 to 61]). The previously published mean KOOS-QoL score from active individuals (with no history of knee injury) was 92 [95% CI: 92 to 93]. Based on this data, athletes with PFP had worse knee-related QoL relative to norms from an active population (mean difference: 14; [KOOS-QOL 95% CI: 70 to 86]).


240	
241	Knee-related QoL in individuals with PFP compared to pain-free controls
242	Three included studies <sup>36,39,42</sup> provided KOOS-QoL data from three different groups of pain-
243	free individuals (i.e. 69 females) and the pooled mean KOOS-QoL score was 98 [95% CI: 97
244	to 100]. Based on the pooled scores, individuals with PFP had worse knee-related QoL
245	relative to pain-free controls (mean difference: 51).
246	
247	Health-related QoL in individuals with PFP
248	Fourteen studies reported health-related QoL in individuals with PFP using SF-36, SF-8, and
249	EQ-5D measures. Eleven studies reported on QoL using the SF-36; eight of these studies
250	reported SF-36 domain scores, 4,5,11,12,14,20,27,32 seven studies reported SF-36 summary
251	scores <sup>2,4,5,16,20,32,49</sup> and four reported both domain and summary scores. <sup>4,5,20,32</sup> One paper used
252	the SF-8 <sup>57</sup> and two studies used the EQ-5D <sup>36,41</sup> (one study used a youth version (EQ-5D-Y)). <sup>36</sup>
253	
254	Pooled SF-36 domain scores from 7 studies (4 higher quality <sup>4,5,14,32</sup> and 3 lower quality <sup>11,20,27</sup> )
255	in individuals with PFP were: physical function 59 [95% CI: 45 to 74], role physical 50 [95%
256	CI: 41 to 60], bodily pain 49 [95% CI: 45 to 53], general health 57 [95% CI: 50 to 66],
257	vitality 54 [95% CI: 49 to 58], social function 67 [95% CI: 55 to 79], role emotional 61 [95%
258	CI: 50 to 73] and mental health 64 [95% CI: 55 to 72]. A single study reported health-related
259	QoL (SF-36 domains) in amateur and professional athletes with PFP <sup>12</sup> (Table 4). Pooled SF-
260	36 PCS and MCS scores from 7 studies (4 higher quality <sup>4,5,32,49</sup> and 3 lower quality <sup>2,16,20</sup> )
261	were 47 [95% CI: 41 to 53] and 54 [95% CI: 47 to 62] respectively.
262	
263	A PFP subgroup from a single study <sup>57</sup> of individuals with knee pain-related diagnoses
264	reported health-related QoL measured with SF-8 (physical function 49 [95% CI: 46 to 52],
265	role physical 39 [95% CI: 36 to 42], bodily pain 35 [95% CI: 30 to 39], general health 43

266	[95% CI: 41 to 46], vitality 51 [95% CI: 48 to 53], social function 46 [95% CI: 43 to 49], role
267	emotional 51 [95% CI: 49 to 54] and mental health 48 [95% CI: 46 to 51]).
268	
269	Two studies reported health-related QoL in individuals with PFP measured with EQ-5D, 36,41
270	but were unable to be pooled as they used different versions of the EQ-5D and one study <sup>36</sup>
271	reported median score rather than mean. Scores from these 2 studies were mean 0.75
272	[standard deviation (SD)=0.12] <sup>41</sup> and median 0.72 [interquartile range 0.68-0.78]. <sup>36</sup>
273	
274	Health-related QoL in indiviudals with PFP compared to population norms
275	Relative to previously reported mean SF-36 domain scores from a general population
276	sample, <sup>29</sup> individuals with PFP had worse health-related QoL (mean difference: physical
277	function=34, role physical=36, bodily pain=30, general health=24, vitality=6, social
278	function=20, role emotional=23 and mental health=14). Additionally, amateur and
279	professional athletes with PFP from a single study, also had worse health-related QoL when
280	compared to previously published SF-36 scores from an active general population sample
281	(Table 4). <sup>23</sup>
282	
283	Health-related QoL in individuals with PFP compared to pain-free controls
284	Compared to mean SF-36 domain scores in pain-free controls, <sup>5</sup> individuals with PFP had
285	worse health-related QoL (mean difference: physical function=38, role physical=47, bodily
286	pain=43, general health=25, vitality=18, social function=30, role emotional=37 and mental
287	health=16) (Figure 3).





PFP






FIGURE 3: Health-related quality of life in individuals with patellofemoral pain.

289

290

291

288

Individuals with PFP also had worse health-related QoL based on SF-36 PCS and MCS when compared to data from pain-free controls<sup>5</sup> (mean difference: PCS=41, MCS=32) (Table 1).

Only one study reported EQ-5D scores in individuals with PFP (median score: 0.72) compared to pain-free controls (median score: 1.00).<sup>36</sup>

## 3.4 Effects of PFP Intervention on QoL

#### Knee-related QoL

Two RCTs reported conflicting evidence for the effect of intervention on KOOS-QoL.<sup>34,41</sup> A lower-quality and high risk of bias study showed that the combined treatment of a knee brace and multi-modal physical therapy, compared to multi-modal physical therapy alone significantly improved knee-related QoL (SMD=0.45 [95% CI: 0.13 to 0.77]).<sup>34</sup> A higher-quality and unclear risk of bias study reported no statistically significant differences in knee-related QoL between individuals with PFP receiving physical-therapist supervised neuromuscular retraining and home exercise with an education session, and those receiving an education session alone (SMD=0.31 [95% CI: -0.05 to 0.67]) (Figure 4).<sup>41</sup>




FIGURE 4: Effect of intervention on quality of life in controlled studies.

Pooled data from three lower-quality repeated measures design studies<sup>6,48,51</sup> provided limited evidence of moderate improvement in knee-related QoL post-intervention (interventions

consisted of brace, off-axis elliptical trainer and tape) compared to pre-intervention (SMD=0.54 [95% CI: 0.04 to 1.04],  $I^2=41\%$ , p=0.03) (Figure 5).




FIGURE 5: Effect of intervention on quality of life in repeated measures studies.

#### Health-related QoL

Two RCTs reported conflicting evidence of the effect of intervention on SF-36 scores. <sup>14,49</sup> A higher-quality and low risk of bias study investigated the effect of multi-modal physical therapy compared to a placebo intervention and found no significant differences between the domain scores of the two groups (Tables 1 and 2). <sup>14</sup> Another higher-quality but high risk of bias study investigated the effects of two multi-modal physical therapy treatments; one based on McConnell taping and selective vastus medialis obliquus exercise (VMO), and the other comprised of sling taping and quadriceps strengthening. <sup>49</sup> QoL outcomes were compared to a (no treatment) control group. Large improvements were observed following analysis of combined mean PCS scores following multi-modal physical therapy for all treated individuals (SMD=0.93 [95% CI: 0.41 to 1.46]) relative to the control group. There was no significant difference in PCS or MCS scores between intervention groups. Large PCS score

327	improvements were observed following analysis of each intervention group compared to no
328	intervention; McConnell taping plus VMO exercise group (SMD=0.84 [95% CI: 0.23 to
329	1.44]) and the sling taping plus quadriceps strengthening group (SMD=0.87 [95% CI: 0.26 to
330	1.48]) (Figure 4). <sup>49</sup>
331	
332	Four repeated measures design studies reported health-related QoL pre- and post-
333	intervention. <sup>2,16,20,27</sup> Pooled SF-36 summary scores from three lower-quality studies <sup>2,16,20</sup>
334	provided limited evidence of large improvements in health-related QoL (PCS SMD=1.36
335	[95% CI: 0.19 to 2.54], $I^2$ =92%, p=0.02, MCS SMD=0.46 [95% CI: 0.06 to 0.85], $I^2$ =46%,
336	p=0.02) post-intervention (strengthening, biomechanical foot-worn device) relative to pre-
337	intervention (Figure 5). A lower-quality study investigated two intervention for PFP: (i)
338	Kinesio taping plus exercise program, and (ii) electrical stimulation of VMO plus exercise
339	program. <sup>27</sup> Compared to pre-intervention, both interventions resulted in significant
340	improvements in SF-36 domain scores, except for vitality. <sup>27</sup>
341	
342	3.5 Factors associated with QoL in Individuals with PFP
343	Due to the very limited number of controlled studies, random effects meta-analysis to
344	determine factors related to QoL outcomes in individuals with PFP could not be performed.
345	
346	4.0 DISCUSSION
347	4.1 QoL in Individuals with PFP
348	This systematic review revealed that individuals with PFP had substantially worse knee- and
349	health-related QoL relative to pain-free controls (KOOS-QoL mean difference: 51, SF-36
350	domains mean difference range: 16-47) and population norms (KOOS-QoL mean difference:
351	37, SF-36 domains mean difference range: 14-36). Impairments in knee- and health-related

352	QoL, were highlighted by the fact that pooled PFP mean 95% CI upper limits were all lower
353	than the 95% CI lower limits for pain-free and normative QoL group means. Impairments in
354	SF-36 PCS scores in individuals with PFP compared to the reference group, were greater than
355	MCS scores, suggesting an emphasis on addressing physical impairments is needed to
356	improve QoL in individuals with PFP.
357	
358	Recent systematic reviews indicate similar impairments in KOOS-QoL for a range of other
359	knee conditions, including knee osteoarthritis (pooled mean=35) <sup>13</sup> , anterior cruciate ligament
360	(ACL) injury (pooled mean=44) <sup>13</sup> , and 5-16 years following ACL reconstruction (pooled
361	mean=74) <sup>17</sup> . Our findings indicate that the impact of PFP (pooled mean=47) on knee-related
362	QoL approaches that of knee osteoarthritis. Additionally, knee-related QoL impairment in
363	people with PFP is similar or greater than QoL impairment following ACL injury, which is
364	considered to be a life-changing event with substantial physical and psychological
365	impacts. <sup>25,43</sup>
366	
367	Our findings indicate athletetic cohorts with PFP (e.g. KOOS-QoL = 78) <sup>12,47</sup> have better
368	knee- and health-related QoL compared to pooled findings of PFP cohorts without inclusion
369	based on athletic status (e.g. KOOS-QoL = 47). This finding is not surprising considering
370	athletes generally have an increased perception of their health in comparison with age-
371	matched peers. 9,23,47 However, when compared to QoL norms measured in active populations,
372	our findings indicate both knee- and health-related QoL was impaired in athletes with PFP.
373	
374	4.2 Effects of PFP Intervention on QoL
375	Findings from repeated measure intervention studies indicate that knee- and health-related
376	QoL improved following interventions for PFP including bracing, taping and exercise

therapy. Importantly, these improvements are greater than the minimal clinically important improvement (MCII) reported for KOOS-QoL (8-10 points)<sup>44</sup> and the SF-36 PCS and MCS (5-7 points).<sup>60,61</sup> However, less improvement was observed in SF-36 MCS scores (mean difference improvement: 6 points), perhaps reflecting the greater impairment in PCS compared with MCS at baseline. Significant improvements in knee- and health- related QoL following intervention in these repeated measure studies should be interpreted with caution. Importantly, a lack of control or comparison group means it is unclear if these improvements were the result of the intervention, placebo, physical-therapist interaction, natural history, or a combination of these factors.<sup>53</sup> Unfortunately, there are currently very few RCTs to provide further insight.

Very limited evidence from one RCT, indicated that despite significant improvements in pain and function, knee-related QoL did not improve more following physical-therapy intervention (i.e., patellofemoral soft tissue mobilisation, strength exercises, neuromuscular training) plus education in comparison to education alone. It is possible that the KOOS-QoL subscale (assessing lifestyle modification, knee awareness, knee confidence and knee difficulties) may not be sensitive to changes in knee pain and function. Similarly, two RCTs reported significant improvements in pain and function for individuals that received multimodal physical therapy compared to controls, but the impact of intervention on health-related QoL was conflicting. Physical interventions may need to be specifically developed in order to target improvements in knee- and health-related QoL. Further research is needed to determine the most effective interventions for improving QoL in individuals with PFP.

Interestingly, Rathleff et al 2014, was the only RCT to encourage ongoing self management and exercise in the longer term (i.e. 12 months) and was also the only controlled study

term follow up (i.e. 12 months), specifically in adolescents. This may indicate t	hat improving
QoL in individuals with PFP requires longer-term physical interventions and f	follow up (e.g.
beyond the common 6-12 week clinical trial period), although further research	h is needed to
confirm this, particularly in adults.	

#### 4.3 Limitations and Recommendations for Future Research

Firstly, all relevant studies were included regardless of methodological quality due to the paucity of research in this area. Therefore, low-quality studies may bias the findings. To account for this, the levels of evidence reported in this review involve consideration of study homogeneity, quality and quantity.

Previously published normative QoL data from Norway<sup>29</sup> and Sweden<sup>33</sup> were used for comparison as these were the largest published normative samples. However the comparison between Scandinavian normative QoL data and pooled QoL data from individuals with PFP from many different countries, may have biased these results.<sup>1</sup> Although chronic musculoskeletal conditions have been shown to have a similar impact on health-related QoL measured by the SF-36 in eight (Western) countries<sup>3</sup>, comparison with non-Western cultures is complex<sup>52</sup> and such analysis is beyond the scope of this review.

Pain-free control group QoL data was very limited (i.e., 4 studies) which may bias pooled mean knee- and health-related QoL comparisons against individuals with PFP. Additionally, three of the four control groups were comprised of adolescent and adult women and lower health-related QoL scores have been reported in women compared to men. <sup>10,26</sup> However, due to the small number of included studies reporting QoL data for men and women, sex-based

analyses were not conducted. Given sex-based differences associated with PFP, future research should consider reporting data for men and women separately.
research should consider reporting data for men and women separately.
Most intervention studies included in this systematic review measured knee- or health-related
QoL as a secondary outcome, and hence may be underpowered to detect changes in QoL.59
Considering we found markedly impaired QoL in individuals with PFP, future research
should consider QoL measures as a primary intervention target and power participant
recruitment accordingly. We were unable to determine whether other participant or
methodological factors are associated with QoL in individuals with PFP, due to the small
number of controlled studies published.
5.0 CONCLUSION
Individuals with PFP aged under 50 years, have impaired knee- and health-related QoL
compared to the general population and pain-free individuals. Based on current evidence,
including a paucity of high quality randomised controlled trials, it is unclear whether
common interventions provided to individuals with PFP have any beneficial effect on knee-
and health-related QoL when compared to a control group. Developing treatments to target
knee-related and health-realted QoL in individuals with PFP and evaluating their efficacy in
longer-term, high-quality randomized controlled trials is urgently needed.

452

453

454

455

#### **REFERENCES**:

- 456 1. Aaronson N, Acquadro C, Alonso J, et al. International quality of life assessment (IQOLA) project. *Quality of life research*. 1992;1(5):349-351.
- 458 2. Akkurt E, Salli A, Ozerbil OM, Ugurlu H. The effect of isokinetic exercise on symptoms,
  459 functional status and EMG activation onset time of the vastus medialis oblique and vastus
  460 lateralis in female patients with patellofemoral pain syndrome. *Isokinetics & Exercise*461 *Science*. 2010;18(3):157-161.
- 462 3. Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: Results from the International Quality of Life Assessment (IQOLA) Project. *Quality of Life Research*. 2004;13(2):283-298.
- 465 4. Apivatgaroon A, Angthong C, Sanguanjit P, Chernchujit B. The validity and reliability of the 466 Thai version of the Kujala score for patients with patellofemoral pain syndrome. *Disability* 467 *and rehabilitation*. 2016;38(21):2161-2164.
- 468 5. Assa T, Elbaz A, Mor A, et al. Gait metric profile of 157 patients suffering from anterior knee pain. A controlled study. *The Knee.* 2013;20(1):40-44.
- 470 6. Banan M, Talebi G, M TD. A study on the effects of patellar taping on pain, quality of life and radiographic findings in patients with patellofemoral pain syndrome. 2016.
- 472 7. Blond L, Hansen L. Patellofemoral pain syndrome in athletes: a 5.7-year retrospective follow-473 up study of 250 athletes. *Acta Orthop Belg.* 1998;64(4):393-400.
- 8. Borenstein M. *Introduction to meta-analysis*. Oxford: Oxford: Wiley; 2009.
- Cameron KL, Thompson BS, Peck KY, Owens BD, Marshall SW, Svoboda SJ. Normative values
   for the KOOS and WOMAC in a young athletic population: history of knee ligament injury is
   associated with lower scores. *The American journal of sports medicine*. 2013;41(3):582-589.
- 478 10. Cherepanov D, Palta M, Fryback DG, Robert SA. Gender differences in health-related quality479 of-life are partly explained by sociodemographic and socioeconomic variation between adult
  480 men and women in the US: evidence from four US nationally representative data sets.
  481 *Quality of life research.* 2010;19(8):1115-1124.
- Cheung RTh, Ngai SPc, Lam PL, Chiu JKw, Fung EYh. Chinese translation and validation of the
   Kujala scale for patients with patellofemoral pain. *Disability & Rehabilitation*.
   2012;34(6):510-513.
- Cheung RTH, Zhang Z, Ngai SPC. Different Relationships Between the Level of Patellofemoral Pain and Quality of Life in Professional and Amateur Athletes. *PM&R*. 2013;5(7):568-572.
- 487 13. Collins NJ, Prinsen CAC, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and
  488 Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement
  489 properties. *Osteoarthritis and Cartilage*. 2016;24(8):1317-1329.
- 490 14. Crossley K, Bennell K, Green S, Cowan S, McConnell J. Physical Therapy for Patellofemoral 491 Pain: A Randomized, Double-Blinded, Placebo-Controlled Trial. *The American Journal of* 492 *Sports Medicine*. 2002;30(6):857-865.
- Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *Journal of Epidemiology and Community Health*. 1998;52(6):377-384.
- 496 16. Eapen C, Nayak CD, Pazhyaottyil Zulfeequer C. Effect of Eccentric Isotonic Quadriceps Muscle
   497 Exercises on Patellofemoral Pain Syndrome: An Exploratory Pilot Study. *Asian Journal of* 498 Sports Medicine. 2011;2(4):227-234.

- 499 17. Filbay SR, Ackerman IN, Russell TG, Macri EM, Crossley KM. Health-Related Quality of Life
   500 After Anterior Cruciate Ligament Reconstruction: A Systematic Review. *The American Journal* 501 of Sports Medicine. 2014;42(5):1247-1255.
- 502 18. Gail M. Sullivan, Richard Feinn. Using Effect Size—or Why the P Value Is Not Enough. *Journal of Graduate Medical Education*. 2012;4(3):279-282.
- 504 19. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Annals of internal medicine*. 1993;118(8):622-629.
- Haim A, Segal G, Elbaz A, et al. The outcome of a novel biomechanical therapy for patients suffering from anterior knee pain. *The Knee.* 2013;20(6):595-599.
- Hart HF, Stefanik JJ, Wyndow N, Machotka Z, Crossley KM. The prevalence of radiographic
   and MRI-defined patellofemoral osteoarthritis and structural pathology: a systematic review
   and meta-analysis. Br J Sports Med. 2017:bjsports-2017-097515.
- Higgins JPT, Altman DG, xf, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ: British Medical Journal.* 2011;343(7829):889-893.
- Huffman GR, Park J, Roser-Jones C, Sennett BJ, Yagnik G, Webner D. Normative SF-36 values in competing NCAA intercollegiate athletes differ from values in the general population. *The Journal of Bone & Joint Surgery.* 2008;90(3):471-476.
- 516 24. Iversen MD, Price LL, von Heideken J, Harvey WF, Wang C. Physical examination findings and
   517 their relationship with performance-based function in adults with knee osteoarthritis. BMC
   518 musculoskeletal disorders. 2016;17(1):273.
- Janssen K, Orchard J, Driscoll T, Van Mechelen W. High incidence and costs for anterior
   cruciate ligament reconstructions performed in Australia from 2003–2004 to 2007–2008:
   time for an anterior cruciate ligament register by Scandinavian model? Scandinavian journal
   of medicine & science in sports. 2012;22(4):495-501.
- 523 26. Jörngården A, Wettergen L, von Essen L. Measuring health-related quality of life in 524 adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the 525 influence of age, gender, and method of administration. *Health and quality of life outcomes*. 526 2006;4(1):91.
- 527 27. Kuru T, Yalıman A, Dereli EE. Comparison of efficiency of Kinesio® taping and electrical stimulation in patients with patellofemoral pain syndrome. *Acta orthopaedica et traumatologica turcica*. 2011;46(5):385-392.
- 530 28. Lankhorst N, van Middelkoop M, Crossley K, et al. Factors that predict a poor outcome 5–8 531 years after the diagnosis of patellofemoral pain: a multicentre observational analysis. *Br J* 532 *Sports Med.* 2015:bjsports-2015-094664.
- 533 29. Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. *Scandinavian Journal of Public Health.* 1998;26(4):250-258.
- Moher D, Liberati A, Tetzlaff J, Altman DG, and the PG. Preferred reporting items for
   systematic reviews and meta-analyses: The prisma statement. *Annals of Internal Medicine*.
   2009;151(4):264-269.
- Mølgaard C, Rathleff MS, Simonsen O. Patellofemoral Pain Syndrome and Its Association
   with Hip, Ankle, and Foot Function in 16- to 18-Year-Old High School Students. *Journal of the American Podiatric Medical Association*. 2011;101(3):215-222.
- Negahban H, Pouretezad M, Sohani SM, Mazaheri M, Salavati M, Mohammadi F. Validation
   of the Persian version of Functional Index Questionnaire (FIQ) and Modified FIQ in patients
   with patellofemoral pain syndrome. *Physiotherapy theory and practice*. 2013;29(7):521-530.
- 544 33. Paradowski PT, Bergman S, Sundén-Lundius A, Lohmander LS, Roos EM. Knee complaints 545 vary with age and gender in the adult population. Population-based reference data for the 546 Knee injury and Osteoarthritis Outcome Score (KOOS). *BMC musculoskeletal disorders*. 547 2006;7(1):38.

- 548 34. Petersen W, Ellermann A, Rembitzki IV, et al. Evaluating the potential synergistic benefit of a 549 realignment brace on patients receiving exercise therapy for patellofemoral pain syndrome: 550 a randomized clinical trial. *Archives of orthopaedic and trauma surgery.* 2016:1-8.
- 551 35. Powers CM. The influence of altered lower-extremity kinematics on patellofemoral joint dysfunction: a theoretical perspective. *Journal of Orthopaedic & Sports Physical Therapy.* 2003;33(11):639-646.
- 36. Rathleff CR, Baird WN, Olesen JL, Roos EM, Rasmussen S, Rathleff MS. Hip and Knee Strength
   Is Not Affected in 12-16 Year Old Adolescents with Patellofemoral Pain A Cross-Sectional
   Population-Based Study. *PLoS ONE*. 2013;8(11):e79153.
- 37. Rathleff CR, Olesen JL, Roos EM, Rasmussen S, Rathleff MS. Half of 12-15-year-olds with knee pain still have pain after one year. *Dan Med J.* 2013;60(11):A4725.
- 38. Rathleff M, Rathleff C, Crossley K, Barton C. Is hip strength a risk factor for patellofemoral
   pain? A systematic review and meta-analysis. *British journal of sports medicine*.
   2014:bjsports-2013-093305.
- Rathleff MS, Petersen KK, Arendt-Nielsen L, Thorborg K, Graven-Nielsen T. Impaired
   conditioned pain modulation in young female adults with long-standing patellofemoral pain:
   a single blinded cross-sectional study. *Pain Medicine*. 2016:pnv017.
- Rathleff MS, Rathleff CR, Olesen JL, Rasmussen S, Roos EM. Is Knee Pain During Adolescence a Self-limiting Condition? *The American Journal of Sports Medicine*. 2016;44(5):1165-1171.
- Rathleff MS, Roos EM, Olesen JL, Rasmussen S. Exercise during school hours when added to patient education improves outcome for 2 years in adolescent patellofemoral pain: a cluster randomised trial. *British Journal of Sports Medicine*. 2014;49(6):406-412.
- Rathleff MS, Samani A, Olesen JL, et al. Neuromuscular activity and knee kinematics in adolescents with patellofemoral pain. *Medicine and science in sports and exercise*. 2013;45(9):1730-1739.
- Risberg MA, Grindem H, Øiestad BE. We Need to Implement Current Evidence in Early
   Rehabilitation Programs to Improve Long-Term Outcome After Anterior Cruciate Ligament
   Injury. Journal of Orthopaedic & Sports Physical Therapy. 2016;46(9):710-713.
- Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. *Health and quality of life outcomes*. 2003;1(1):64.
- Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis
   Outcome Score (KOOS)—Development of a Self-Administered Outcome Measure. *Journal of Orthopaedic & Sports Physical Therapy.* 1998;28(2):88-96.
- 581 46. Sanders C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. *Bmj.* 1998;317(7167):1191-1194.
- 583 47. Silva DdO, Coura MB, Waiteman M, et al. Patellofemoral pain and sports practice: reduced 584 symptoms and higher quality of life in adolescent athletes as compared to non-athletes. 585 *Motriz: Revista de Educação Física*. 2016;22:84-89.
- 586 48. Sinclair JK, Selfe J, Taylor PJ, Shore HF, Richards JD. Influence of a knee brace intervention on perceived pain and patellofemoral loading in recreational athletes. *Clinical Biomechanics*. 2016;37:7-12.
- 589 49. Syme G, Rowe P, Martin D, Daly G. Disability in patients with chronic patellofemoral pain 590 syndrome: A randomised controlled trial of VMO selective training versus general 591 quadriceps strengthening. *Manual Therapy*. 2009;14(3):252-263.
- 592 50. Tornbjerg SM, Nissen N, Englund M, et al. Structural pathology is not related to patient-593 reported pain and function in patients undergoing meniscal surgery. *Br J Sports Med.* 594 2016:bjsports-2016-096456.
- Tsai L-C, Lee SJ, Yang AJ, Ren Y, Press JM, Zhang L-Q. Effects of off-axis elliptical training on reducing pain and improving knee function in individuals with patellofemoral pain. *Clinical journal of sport medicine: official journal of the Canadian Academy of Sport Medicine*.
   2015;25(6):487.

- Tseng H-M, Lu J-fR, Gandek B. Cultural Issues in Using the SF-36 Health Survey in Asia: Results from Taiwan. *Health and Quality of Life Outcomes*. 2003;1(1):72.
- Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. *JAMA*. 1994;271(20):1609-1614.
- 54. van der Heijden RA, Lankhorst NE, van Linschoten R, Bierma-Zeinstra S, van Middelkoop M.
   604 Exercise for treating patellofemoral pain syndrome. *The Cochrane Library*. 2015(1).
- 55. Van Middelkoop M, Van Linschoten R, Berger MY, Koes BW, Bierma-Zeinstra SM. Knee
   complaints seen in general practice: active sport participants versus non-sport participants.
   BMC musculoskeletal disorders. 2008;9(1):36.
- Van Tulder M, Furlan A, Bombardier C, Bouter L, Group EBotCCBR. Updated method
   guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine.
   2003;28(12):1290-1299.
- Vincent HK, Lamb KM, Day TI, Tillman SM, Vincent KR, George SZ. Morbid obesity is
   associated with fear of movement and lower quality of life in patients with knee pain-related
   diagnoses. PM&R. 2010;2(8):713-722.
- Viswanathan M, Patnode CD, Berkman ND, et al. Recommendations for assessing the risk of
   bias in systematic reviews of health-care interventions. *Journal of Clinical Epidemiology*.
   2018;97:26-34.
- 59. Waal JMvd, Terwee CB, Windt DAvd, Bouter LM, Dekker J. The impact of non-traumatic hip
   618 and knee disorders on health-related quality of life as measured with the SF-36 or SF-12. A
   619 systematic review. Quality of Life Research. 2005;14(4):1141-1155.
- 620 60. Ward MM, Guthrie LC, Alba MI. Clinically Important Changes in Short Form 36 Health Survey
   621 Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness.
   622 Arthritis Care Res (Hoboken). 2014;66(12):1783-1789.
- 623 61. Ware JE, Kosinski M, Dewey JE, Gandek B. *SF-36 health survey: manual and interpretation guide.* Quality Metric Inc.; 2000.
- 625 62. Wood L, Muller S, Peat G. The epidemiology of patellofemoral disorders in adulthood: a 626 review of routine general practice morbidity recording. *Primary Health Care Research & Development*. 2011;12(2):157-164.

628

## APPENDIX 1: Search Strategy for MEDLINE

CONCEPT	KEYWORDS	MESH HEADING	
Patellofemoral	1. anterior knee pain.mp.	5. Patella/ or Knee joint/ or Knee/ AND Pain/ or	
pain	2. patella* or femoropatell* or retropatell* or patellofemoral or	Arthralgia/	
	patello-femoral <i>adj2</i> pain or syndrome or dysfunction.mp	6. Patellofemoral pain syndrome/	
	3. lateral compression or lateral facet or lateral pressure or odd facet	7. Chondromalacia Patellae/	
	adj2 syndrome.mp	Y	
	4. chondromalac* or chondropath* or chondrosis <i>adj2</i> patell* or		
	femoropatell* or retropatell* or femoro-patell*.mp.	C Y	
			8. OR/1-7
			0. OR/1-7
Quality of life	9. Knee Injury and Osteoarthritis Outcome Score or KOOS.mp.	14. Quality of life/	
	10. Short?form 36 OR SF?36 OR Short?form 12 OR SF?12 OR Short		
	Form Health Survey.mp.		
	11. EQ5D OR EQ-5D*.mp.		
	12. QOL OR AQOL OR Health related quality of life or HRQOL.mp.		
	13. lower extremity activity profile or leap.mp	$\supset$	15. OR/9-14
		7	
			16. 8. AND 15.

**APPENDIX 2**. Modified Downs & Black checklist for methodological quality appraisal.

Item	Title	Description by Downs& Black	Yes	No/Unable to determine	Partially	Inter- vention	Cross- section	Validity
1	Aim	Is the hypothesis/aim/objective clearly described?	1	0	<b>Y</b>			
2	Outcomes	Are the main outcomes to be measured clearly described in the Introduction or Methods section?	1	0	/			
3	Participants	Are the characteristics of the patients included in the study clearly described?	1	0				
5	Confounders	Are distributions of principal confounders in each group of subjects to be compared clearly described?	2	0	1			N/A
6	Findings	Are the main findings of the study clearly described?	1	0				
7	Random variability	Does the study provide estimates of the random variability in the data for the main outcomes		0				
10	Probability	Have actual probability values been reported for the main outcomes except where the probability value in less than 0.001?	1	0				N/A
11	External validity	Were the subjects asked to participate in the study representative of the entire population from which they were recruited?	1	0				
12	External validity	Were those subjects who were prepared to participate representative of the entire population from which they were recruited?	1	0				
15	Blinding	Was an attempt made to blind those measuring the main outcomes of the intervention?	1	0				N/A
18	Statistical tests	Were the statistical tests used to assess the main outcomes appropriate?	1	0				N/A
20	Accurate outcomes	Were the main outcome measures used accurate (valid and reliable)?	1	0				
25	Confounding adjustment	Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?	1	0				N/A
26	Loss to follow- up	Were losses of patients to follow-up taken into account?	1	0			N/A	N/A
27	Power	Did the study have sufficient power to detect a clinically important effect where probability value for difference being due to chance is < 5%	1	0				N/A
	Max score	<i>Y</i>	16			16	15	8

Note. N/A is not applicable

#### **HIGHLIGHTS**

People with patellofemoral pain have impaired quality of life

Quality of life is worse than the general population

Quality of life is worse than pain-free people

Physical therapy may improve quality of life